The Limits of Collaborative Care: Why the CLARO Trial Found No Added Benefit for OUD and Comorbid Mental Illness
Posted inInternal Medicine news Psychiatry

The Limits of Collaborative Care: Why the CLARO Trial Found No Added Benefit for OUD and Comorbid Mental Illness

The CLARO randomized clinical trial investigated whether a collaborative care model could improve outcomes for patients with opioid use disorder and co-occurring depression or PTSD. The study found no statistically significant advantages over enhanced usual care, suggesting challenges in implementing these models for complex, low-resource populations.
Optimizing Opioid Use Disorder Treatment: When Does 300 mg Outperform 100 mg of Extended-Release Buprenorphine?
Posted innews Psychiatry Public Health

Optimizing Opioid Use Disorder Treatment: When Does 300 mg Outperform 100 mg of Extended-Release Buprenorphine?

This randomized clinical trial compares 100-mg and 300-mg maintenance doses of extended-release buprenorphine. While overall efficacy was similar, the 300-mg dose significantly improved abstinence among patients with high-frequency fentanyl use, suggesting a need for dose-intensification in the era of potent synthetic opioids.
Evaluating the Role of Behavioral Therapy in Enhancing Buprenorphine Treatment Outcomes for Opioid Use Disorder: Insights from a Secondary Analysis of Four Randomized Clinical Trials
Posted inPsychiatry Specialties

Evaluating the Role of Behavioral Therapy in Enhancing Buprenorphine Treatment Outcomes for Opioid Use Disorder: Insights from a Secondary Analysis of Four Randomized Clinical Trials

A secondary analysis of four randomized trials reveals that additional behavioral therapy does not significantly improve opioid abstinence, retention, or functional outcomes when added to buprenorphine and medical management in opioid use disorder treatment.